SCHEMBL6914151

SCHEMBL6914151

O=C(Nc1ccc(N2C(=O)CCC2=O)c(Cl)c1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.72
RAB9A P51151 6/20 0.61
NPC1 O15118 4/20 0.61
CHRM1 P11229 1/20 0.60
GRM1 Q13255 2/20 0.58
ALDH1A1 P00352 4/20 0.55
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPT P10636 5/20 0.51
LMNA P02545 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 2/20 0.51
HTT P42858 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CNR1 P21554 1/20 0.50
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914270 0.87 GRM4 (0.69) GRM4RAB9ANPC1GRM1ALDH1A1
SCHEMBL11712114 0.85 GRM4 (0.64) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL1897912 0.84 GRM4 (1.00) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL1902023 0.80 GRM4 (0.73) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL1897536 0.78 GRM4 (0.70) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL6914155 0.78 GRM4 (0.70) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL1897953 0.78 GRM4 (0.73) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL3783679 0.77 GRM4 (0.79) GRM4RAB9ANPC1ALDH1A1MAPT
SCHEMBL1895474 0.77 GRM1 (0.72) GRM4GRM1CYP1A2CYP2C9CYP2C19
SCHEMBL30369807 0.77 NPC1 (1.00) GRM4RAB9ANPC1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759377-B2 Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2014-06-24 US disclosed
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIA4, GRIK4 GRM4 1/4885RAB9A 3184/4885NPC1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.